13D Filing: Viking Global and Arbutus Biopharma Corp (ABUS)

Page 2 of 17 – SEC Filing

CUSIP No. 03879J100 13D Page 2 of 16 Pages
1

NAMES OF REPORTING PERSONS

Viking Global Investors LP

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)
o

(b)
x

3  SEC USE ONLY
4

SOURCE OF FUNDS (see instructions)

OO (See Item 3)

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) o
6

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES

BENEFICIALLY OWNED BY
EACH REPORTING

PERSON WITH

7

SOLE VOTING POWER

0

8

SHARED VOTING POWER

0

9

SOLE DISPOSITIVE POWER

0

10

SHARED DISPOSITIVE POWER

16,013,540

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON

16,013,540

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) o
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

29.1%*

14

TYPE OF REPORTING PERSON

PN

* The calculation assumes that there are a total of 55,024,557 Common Shares outstanding
as of April 30, 2017, as reported by the Issuer (as defined below) on its Quarterly Report on Form 10-Q for the period ended March
31, 2017, filed with the Securities and Exchange Commission (the “SEC”) on May 4, 2017.
Follow Arbutus Biopharma Corp (NASDAQ:ABUS)